Publications by authors named "P Thompson-Leduc"
Article Synopsis
- Cytokine release syndrome (CRS) can happen after cancer immunotherapies, like blinatumomab or CAR-T therapy, and while it's mostly mild, it can still be serious in some cases (high-grade CRS).
- An algorithm was tested to detect CRS using various data sources, showing good sensitivity (77%-100% for any CRS) but poorer performance for high-grade CRS (8%-80%), which varied by database type.
- The study utilized a LASSO regression model to identify signs of high-grade CRS, finding indicators like hypotension and the use of certain medications (tocilizumab, vasopressors) that may signal severity in retrospective reviews.
Comparison of Time to Next Treatment or Death Between Front-Line Daratumumab, Lenalidomide, and Dexamethasone (DRd) Versus Bortezomib, Lenalidomide, and Dexamethasone (VRd) Among Transplant-Ineligible Patients With Multiple Myeloma.
Cancer Med
November 2024
Article Synopsis
- Daratumumab, lenalidomide, and dexamethasone (DRd) and bortezomib, lenalidomide, and dexamethasone (VRd) are the main treatment options for patients with newly diagnosed multiple myeloma who cannot undergo a transplant.
- This study compared the time until patients needed new treatment or died (TTNT) between those receiving DRd and VRd using real-world data from a recent database.
- The results showed that patients treated with DRd had a median TTNT of 37.8 months, significantly longer than the 18.7 months for those receiving VRd, indicating that DRd is more effective for this specific patient population.
Purpose: Patients with psoriasis (PsO) and psoriatic arthritis (PsA) are at increased risk of herpes zoster (HZ), but healthcare resource use (HRU) and costs relating to HZ in adults with PsA are unknown. We aimed to estimate the incidence of HZ among adults with PsA vs without psoriatic disease and the additional HRU and costs among patients with PsA with vs without HZ.
Patients And Methods: This retrospective, longitudinal, cohort study estimated HZ incidence in PsA+ vs PsO-/PsA- cohorts and HRU and medical/pharmacy costs among PsA+/HZ+ vs PsA+/HZ- cohorts comprised of adults from Optum's de-identified Clinformatics Data Mart Database during 2015-2020.
Background: Herpes zoster (HZ) is a painful condition caused by reactivation of the varicella-zoster virus. The objectives of this study were to compare HZ incidence in adults with asthma versus adults without asthma and to compare healthcare resource use as well as direct costs in adults with HZ and asthma versus adults with asthma alone in the USA.
Methods: This retrospective longitudinal cohort study included adults aged ≥18 years across the USA.
Introduction: Definitions of moderate asthma exacerbation have been inconsistent, making their economic burden difficult to assess. An algorithm to accurately identify moderate exacerbations from claims data is needed.
Methods: A retrospective cohort study of Reliant Medical Group patients aged ≥18 years, with ≥1 prescription claim for inhaled corticosteroid/long-acting β-agonist, and ≥1 medical claim with a diagnosis code for asthma was conducted.